Scribble

KARD share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Price change

The price of KARD shares has increased $1.66 since the market last closed. This is a 11.98% rise.
Closed at $15.52.

The stock has since risen $0.18 in after-hours trading.

Key terms

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $1.45B

A market capitalization between $300 million and $2 billion places KARD in the small capitalization category.

Key terms

Smart score

Nov 06, 2026 4:34pm ET Kardigan Completes Enrollment in Phase 2b Aortic Stenosis Trial by TipRanks Nov 06, 2026 4:10pm ET Kardigan completes enrollment in KATALYST-AV trial by TipRanks Nov 04, 2026 6:15am ET Kardigan initiated with a Buy at H.C. Wainwright by TipRanks Oct 29, 2026 7:31am ET Kardigan initiated with an Overweight at Cantor Fitzgerald by TipRanks Oct 29, 2026 6:12am ET Kardigan initiated with an Overweight at Cantor Fitzgerald by TipRanks Oct 21, 2026 4:20pm ET Kardigan initiated with an Outperform at Baird by TipRanks Oct 15, 2026 8:40pm ET Kardigan initiated with an Outperform at William Blair by TipRanks Oct 12, 2026 5:40am ET Kardigan initiated with a Buy at UBS by TipRanks Oct 11, 2026 7:15pm ET Analyst Initiates Buy on Kardigan With $25 Price Target Ahead of Key 1H27 Precision Cardiology Data Catalysts by TipRanks Oct 05, 2026 12:30pm ET KARD’s Danicamtiv Trial Progress Puts Genetic Heart Failure in Investor Focus by TipRanks Sep 30, 2026 8:33am ET Kardigan Adds Google Finance Executive to Board Leadership by TipRanks Sep 30, 2026 8:10am ET Kardigan appoints Kristin Reinke to board of directors by TipRanks Sep 23, 2026 8:36am ET Three new option listings on September 23rd by TipRanks Sep 02, 2026 12:30pm ET Kardigan’s Tonlamarsen Trial Targets Severe Hypertension: What Investors Should Watch by TipRanks Sep 02, 2026 12:30pm ET Kardigan’s Danicamtiv Heart Study Moves Forward, Keeping KARD on Investors’ Radar by TipRanks Aug 25, 2026 8:00am ET Kardigan price target lowered to $46 from $51 at JPMorgan by TipRanks Aug 11, 2026 7:11am ET Kardigan reports Q2 EPS ($4.61) vs ($4.64) last year by TipRanks

No recent press releases are available for KARD

1-year income & revenue

KARD total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
KARD net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
KARD earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

How competitors are chosen

KARD's competitors are included in the Health Technology sector and Biotechnology group
Market cap: $1.45B

A market capitalization between $300 million and $2 billion places KARD in the small capitalization category.